These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17517847)

  • 1. In vitro interactions between apricitabine and other deoxycytidine analogues.
    Bethell R; De Muys J; Lippens J; Richard A; Hamelin B; Ren C; Collins P
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2948-53. PubMed ID: 17517847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers.
    Holdich T; Shiveley LA; Sawyer J
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2943-7. PubMed ID: 17242147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
    Cahn P; Wainberg MA
    J Antimicrob Chemother; 2010 Feb; 65(2):213-7. PubMed ID: 20007333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
    Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
    Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
    Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
    Hernandez-Santiago BI; Mathew JS; Rapp KL; Grier JP; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2130-5. PubMed ID: 17403996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz.
    McColl DJ; Margot N; Chen SS; Harris J; Borroto-Esoda K; Miller MD
    HIV Clin Trials; 2011; 12(2):61-70. PubMed ID: 21498149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
    Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.
    Cahn P; Altclas J; Martins M; Losso M; Cassetti I; Cooper DA; Cox S
    HIV Med; 2011 Jul; 12(6):334-42. PubMed ID: 21054750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
    Borroto-Esoda K; Parkin N; Miller MD
    Antivir Chem Chemother; 2007; 18(5):297-300. PubMed ID: 18046962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.
    Quan Y; Gu Z; Li X; Liang C; Parniak MA; Wainberg MA
    J Mol Biol; 1998 Mar; 277(2):237-47. PubMed ID: 9514745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.
    de Muys JM; Gourdeau H; Nguyen-Ba N; Taylor DL; Ahmed PS; Mansour T; Locas C; Richard N; Wainberg MA; Rando RF
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1835-44. PubMed ID: 10428900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.
    Venhoff N; Setzer B; Melkaoui K; Walker UA
    Antivir Ther; 2007; 12(7):1075-85. PubMed ID: 18018766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apricitabine: a nucleoside reverse transcriptase inhibitor for HIV infection.
    Gaffney MM; Belliveau PP; Spooner LM
    Ann Pharmacother; 2009 Oct; 43(10):1676-83. PubMed ID: 19737995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.
    Gallant JE
    AIDS Read; 2006 Oct; 16(10):556-9. PubMed ID: 17096474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
    Miller MD; Haddad M; Su C; Gibbs C; McColl DJ; Guyer B
    Antivir Ther; 2012; 17(6):993-9. PubMed ID: 22837442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.
    Zhou Z; Rodman JH; Flynn PM; Robbins BL; Wilcox CK; D'Argenio DZ
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2686-94. PubMed ID: 16870759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers treated with trimethoprim-sulphamethoxazole.
    Shiveley L; Struthers-Semple C; Cox S; Sawyer J
    J Clin Pharm Ther; 2008 Feb; 33(1):45-54. PubMed ID: 18211616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
    Curran A; Martinez E; Podzamczer D; Lonca M; Barragan P; Crespo M; Falco V; Vidal-Sicart S; Imaz A; Martinez M; Gatell JM; Ribera E
    Antivir Ther; 2012; 17(4):711-8. PubMed ID: 22374987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRTI-associated mutations by apricitabine triphosphate.
    Frankel FA; Coutsinos D; Xu H; Wainberg MA
    Antivir Chem Chemother; 2007; 18(2):93-101. PubMed ID: 17542154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.